Dynavax, DVAX and Surpasses Q4

Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. At the end of the company's prepared remarks,
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations. Reported EPS is $0.05 EPS, expectations were $0.05. Operator: Good day, ladies and gentlemen,
Dynavax Technologies Corp (DVAX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer
Dynavax Technologies: Q4 Earnings Snapshot
Dynavax Technologies Corp. (DVAX) on Thursday reported fourth-quarter earnings of $7.1 million. The Emeryville, California-based company said it had net income of 5 cents per share. The results surpassed Wall Street expectations.
Dynavax Technologies’ (DVAX) Outperform Rating Reaffirmed at William Blair
Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...
Dynavax price target raised to $33 from $29 at Citizens JMP
Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...
Business Wire4d
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NAS ...
Dynavax Technologies climbs as investor begins proxy fight (update)
Adds Dynavax response. Dynavax Technologies (NASDAQ:DVAX) rose 2.8% after a large investor started a proxy fight with the ...
JMP Securities Keeps Their Buy Rating on Dynavax (DVAX)
JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth ...
Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market
Q4 2024 Management View CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving profitability and implementing a share repurchase plan. Looking ahead, ...
Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24
HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...